Bruker BRKR
United StatesHealthcare · Medical DevicesUSD
63.25 USD (+5.9%)
12 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Bruker Corporation is a technology company that designs and manufactures scientific instruments and diagnostic solutions for the life sciences, research, and clinical diagnostics markets.
Key points
from its scores- ✓Good share-price trend9.3
- ✕Demanding valuation4.1
- ✕Little competitive advantage4.2
- ✕Unfavourable risk and backdrop4.6
AI analysis
bottom line, main risk, context and newsThe combination of high debt and negative ROE warrants caution despite good momentum and gross margin.
Bruker shows moderate revenue growth (5.20%) and a healthy gross margin (48.48%), but its financial health is pressured by net debt of 3.09x EBITDA and a negative ROE (-3.00%), limiting its appeal despite strong momentum of 51.98%.
Financial leverage (Net Debt/EBITDA of 3.09) combined with a negative ROE (-3.00%) exposes Bruker to higher financing costs and potential erosion of profitability if the high-rate environment persists.
Context and risks
Bruker operates in the medical devices and scientific equipment sector, an area with active FDA regulatory oversight and pricing pressure in the US market. The governance risk of the country of domicile (United States) is moderate, justifying a slight negative adjustment.
Is Bruker stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 38% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 20.0 | 14.5 | +38% |
| Price / book | 3.8 | 4.1 | −7% |
| Price / sales | 2.6 | 3.4 | −24% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 4.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 63.25 USD, +5.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.2 (sector 5.5), Growth 5.7 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 25.0
- EV / EBITDA
- 20.0
- Price / book
- 3.8
- Price / sales
- 2.6
- PEG
- 1.52
- Market cap
- 9.1B USD
- Enterprise value
- 10.8B USD
Profitability
- ROE
- −3.0%
- ROA
- 3.1%
- ROIC (approx.)
- 8.2%
- Gross margin
- 48.5%
- Operating margin
- 9.9%
- Net margin
- −2.0%
- Free cash flow
- 179.9M USD
- FCF yield
- 2.0%
- Cash conversion
- 33%
Solvency
- Total debt
- 1.9B USD
- Net debt
- 1.7B USD
- Cash
- 184.9M USD
- EBITDA
- 541.1M USD
- Net debt / EBITDA
- 3.09
- Debt / equity
- 76.16
- Current ratio
- 1.85
- Quick ratio
- 0.80
Growth
- Revenue growth
- +5.2%
- EPS (TTM)
- −0.70 USD
- EPS (forward)
- 2.39 USD
Dividend
- Dividend yield
- 0.3%
- Payout
- 38.5%
Risk and market
- Beta
- 1.22
- Analyst consensus
- Buy (12)
- Target price
- 63.25 USD
- 52-week range
- 32.37 – 66.98
Recent news
All BRKR news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Bruker
Is Bruker stock cheap or expensive?
On EV / EBITDA, it trades 38% above the Healthcare median. Valuation score: 4.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 63.25 USD, +5.9% versus the price. This is not investment advice.
What score does Bruker get on MeridIAn Screener?
It scores 5.0 out of 10, rank 1,690 of 2,130 (better than 19% of the companies analysed). Its strongest category is Momentum (9.3) and its weakest, Valuation (4.1). Analysis of 08/10/2026.
How much is Bruker worth on the stock market?
Its market capitalisation is 9.1B USD and its enterprise value, debt included, is 10.8B USD.
How much debt does Bruker have?
Its net debt (debt minus cash) is 1.7B USD. That is 3.09 times its EBITDA; the Healthcare median is 1.53.
Does Bruker pay a dividend?
Yes: its dividend yield is 0.33% and it pays out 38% of its earnings.
How has Bruker stock performed over the last year?
It has risen 70.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 32.37 and 66.98 USD. Past performance does not guarantee future results.
What do analysts think of Bruker?
12 analysts cover it; their average recommendation is “Buy” and their average target is 63.25 USD (+5.9% versus the price). It is an estimate, not market data.